(b) polyethylene glycol;

(c) polyoxyethylated castor oil;

(d) ethanol; and

(e) a pharmaceutically acceptable IV solution selected from the group consisting of a saline solution and a dextrose solution;

wherein the polyethylene glycol and the polyoxyethylated castor oil are present in a 1:1 ratio by weight.

17. The pharmaceutical composition of claim 16, comprising about 200 mg of the free base of *N*-(4-{4-amino-7-[1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]thieno[3,2-*c*]pyridin-3-yl}phenyl)-*N'*-(3-fluorophenyl)urea.

18. The pharmaceutical composition of claim 16 or 17, wherein the polyethylene glycol is polyethylene glycol 300.

19. The pharmaceutical composition of claim 16-18, wherein the polyoxethylated castor oil is polyoxyl 35 castor oil.

20. The pharmaceutical composition of claim 16-19, wherein the IV solution is a 0.45% saline solution.

21. The pharmaceutical composition of claim 16-19, wherein the IV solution is a 0.9% saline solution.

22. The pharmaceutical composition of claim 16, wherein the IV solution is a 5% dextrose solution.

~~23. A method of treating cancer comprising administering to a subject having the disease a therapeutically effective amount of the pharmaceutical composition of claim 1.~~

24. The method of claim 23, wherein the pharmaceutical composition is administered by intravenous administration.